How Hemophilia A Patients Benefit from Emicizumab

A novel therapy called Emicizumab can reduce the incidence of bleeding episodes by 87 percent in patients with hemophilia A inhibitors, finds a Phase II clinical trial. Patients with hemophilia A -- caused by deficiency of coagulation factor VIII -- often experience excessive bleeding in the event of a cut or injury and require prophylactic treatment with intravenously administered factor VIII three times a week. However, repeated administration of clotting factor can increase the development of antibodies called inhibitors. These inhibitors attack and destroy the necessary factor that affects the treatment.